Aller au contenu principal

 Articles scientifiques

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors.

Auteurs : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Année : 2021
Journal : Clin Cancer Res

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Auteurs : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 47-57

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Auteurs : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 37-46

Targeted therapy for breast cancer in older patients.

Auteurs : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Année : 2020
Journal : J Geriatr Oncol
Volume : 11
Pages : 380-388

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Auteurs : Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP
Année : 2020
Journal : Acta Clin Belg
Volume : 75
Pages : 128-135

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Auteurs : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart M, de Azambuja E
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Auteurs : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Année : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 262-273.e7

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Auteurs : Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, DArcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L
Année : 2020
Journal : Lancet Oncol
Volume : 21
Pages : 645-654

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.

Auteurs : Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Année : 2020
Journal : Cancers (Basel)
Volume : 12

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Auteurs : Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A
Année : 2020
Journal : Mol Cancer Ther
Volume : 19
Pages : 468-478

Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.

Auteurs : Farhat F, Tarabaih M, Kanj A, Aoun M, Kattan J, Assi T, Awada A
Année : 2020
Journal : Anticancer Drugs
Volume : 31
Pages : 85-89

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Auteurs : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Année : 2020
Journal : Acta oncologica
Volume : 59
Pages : 1438-1446

Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics.

Auteurs : Fares JE, El Tomb P, Khalil LE, Atwani RW, Moukadem HA, Awada A, El Saghir NS
Année : 2020
Journal : Cancer Treat Rev
Volume : 89
Pages : 102066

Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.

Auteurs : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, de Azambuja E
Année : 2020
Journal : J Natl Cancer Inst

Targeting molecular subtypes in solid cancers: successes and failures.

Auteurs : Assi R, Kotecki N, Awada A
Année : 2020
Journal : Curr Opin Oncol
Volume : 32
Pages : 488-493

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Auteurs : Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 5310-5319

[Tolerablity of everolimus in clinical practice: a retrospective study].

Auteurs : Afani L, Belbaraka R, Awada A
Année : 2020
Journal : Pan Afr Med J
Volume : 36
Pages : 26

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-ß and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.

Auteurs : Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N
Année : 2020
Journal : J Immunother Cancer
Volume : 8

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Auteurs : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Année : 2020
Journal : Clin Colorectal Cancer
Volume : 19
Pages : 311-318.e1

Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity.

Auteurs : Engelman D, Moreau M, Lepida A, Zaouak Y, Paesmans M, Awada A
Année : 2020
Journal : ESMO Open
Volume : 5